MYLAN PHARMACUETICALS, INC. | Search

Accessibility help Skip to navigation Skip to content Skip to footer

Showing results for MYLAN PHARMACUETICALS, INC.

Sort by

Viewing results 1‒25 of 130

Pfizer Inc
Pfizer to buy biotech group Biohaven for $11.6bn
...As well as proceeds from its Covid products, Pfizer has also benefited from the spin-off of its Upjohn generics business, which combined with Mylan to form Viatris in late 2020....
May 10, 2022
Novartis AG
Novartis plans to spin off Sandoz in October
...In 2020, Pfizer spun off its generics business Upjohn, combining it with Mylan to form Viatris, while Johnson & Johnson, GSK, Pfizer and Novartis have all shed their consumer health businesses selling over-the-counter...
August 18, 2023
FT Live
US Pharma and Biotech Summit
Strategies for innovation, pricing and access
Thursday, 16 MayNew York, NY, USA
Coronavirus treatment
WHO calls for lower prices on Gilead drug for Covid-linked black fungus
...Gilead told the FT that in India the price of the drug and the terms of supply are negotiated by the US company Viatris, previously also known as Mylan, which holds the marketing authorisation for AmBisome...
July 1, 2021
Pfizer Inc
Pfizer expects $15bn in Covid vaccine revenue this year
...Results and forecasts exclude its Upjohn unit, as Pfizer closed the transaction to merge the generics business with Mylan during the quarter....
February 2, 2021
Drug prices
Gilead did not seek US exclusivity on PrEP with Truvada
...Mylan, which makes a generic version of Truvada, pays royalties for some its sales to the CDC. When the generic market forms in the US, it said, it will continue to do so....
August 18, 2019
Coronavirus
US hospitals panic-buy drugs ahead of coronavirus influx
...Mylan, a US-based generics maker, has restarted production of hydroxychloroquine at its West Virginia plant and is looking to increase manufacturing outside of the US too....
March 21, 2020
FT Live
Global Pharma and Biotech Summit
Driving life sciences innovation in a disrupted world
Tuesday, 5 NovemberIn-Person & Online Conference
Biogen Inc
Biogen shares soar after patent victory
...In mid-afternoon trading in New York, shares in Mylan, which is in the process of merging with Pfizer’s generics business Upjohn, were up 2.6 per cent to $22.83....
February 5, 2020
Pharmaceuticals sector
Novartis generics unit admits to fixing drug prices
...Teva, Mylan and others in the lawsuits have denied wrongdoing....
March 3, 2020
LexPharmaceuticals sector
Pfizer/Mylan: hard reality Premium content
...The deal with Mylan is similar. Here, however, Pfizer is spinning off Upjohn and then combining it with all of Mylan....
July 29, 2019
Pfizer Inc
Pfizer and Mylan set to merge off-patent drugs businesses
...The plans would also see Mylan’s chief executive Heather Bresch depart, after leading the company for seven years....
July 27, 2019
Pfizer Inc
Pfizer and Mylan to combine off-patent drugs businesses
...The deal comes after a near-50 per cent drop in Mylan shares over the past year as sales slowed. Heather Bresch will retire after eight years as Mylan chief executive when the transaction closes....
July 29, 2019
Merck & Co Inc
Merck plans to spin off assets in effort to streamline its business
...and spinning off their consumer health divisions, which sell over-the-counter products, while Pfizer is in the process of trying to combine its generics business Upjohn with the large generics drugmaker Mylan...
February 5, 2020
Celgene Corp
Amgen to buy Celgene’s Otezla in $13.4bn deal
...agreed in the pharmaceutical and healthcare sector, according to Refinitiv, including AbbVie’s decision to buy the maker of Botox, Allergan, for $63bn; Pfizer’s sale of its off-patent drug business to Mylan...
August 26, 2019
AbbVie Inc
AbbVie raises forecasts despite pressure on Humira
...Rivals entering the market include Amgen, Sandoz, Biogen, Samsung Bioepis and Mylan. In the first quarter, Humira represented 56 per cent of revenue at $4.4bn....
April 25, 2019
Michael Skapinker
EpiPen dearth shows company and regulator failure
...Third, Mylan has exploited its dominant-supplier position....
October 2, 2018
FT Live
Global Private Banking Awards 2024
Celebrating excellence in wealth management
Thursday, 7 NovemberThe Landmark London, London, UK
Equities
Markets Now - Monday 23rd March 2020
...So far, Mylan, Teva, Sandoz, and Amneal have issued press releases discussing plans to build significant amounts of inventory of hydroxychloroquine for treatment of COVID-19....
March 23, 2020
News in-depthPharmaceuticals sector
Rivals line up to take on world’s best-selling drug
...Rajiv Malik, president of Mylan, suggested that quality and continuity of supply, not simply price, must be a factor in payers’ commissioning decisions....
October 14, 2018
US & Canadian companies
Pfizer under pressure to resolve shortage of life-saving EpiPen
...The shortage of EpiPens is particularly irksome for Mylan as it tries to move on from controversy over the cost of the medicine....
May 24, 2018
LexPharmaceuticals sector
AbbVie/arthritis drugs: copycat flap Premium content
...Amgen, Sandoz, Mylan, and Samsung Bioepis launched copycat drugs in Europe two weeks ago. Prices differ between markets but are between 10 and 80 per cent cheaper....
November 2, 2018
Pharmaceuticals sector
Mylan drops as AGs look to expand generic drug-pricing lawsuit
...The companies now under investigation are: Heritage Pharmaceuticals, Inc.; Aurobindo Pharma USA, Inc.; Citron Pharma, LLC; Mayne Pharma (USA), Inc.; Mylan Pharmaceuticals, Inc.; Teva Pharmaceuticals USA;...
October 31, 2017
Personal & Household Goods
Challenges to Botox threaten a market makeover
...Last week, Revance announced it was teaming up with Mylan , the world’s largest generic drugmaker by market value, to develop the biosimilar product, prompting a sell-off in Allergan’s shares....
March 8, 2018
News in-depthEuropean companies
Drugmakers take unorthodox route to boosting biosimilars
...Chrys Kokino, global biologics head for US drugmaker Mylan, which has seen prices for its generic drugs squeezed in recent years, said his own company was “very heavily invested [in] and committed to the...
April 18, 2018
Capital markets
John Paulson takes an axe to his struggling hedge fund
...Paulson & Co’s biggest public holdings, according to regulatory filings, are pharma companies Mylan, Shire, Valeant and Allergan, as well as an exchange-traded fund that tracks the price of gold....
March 16, 2018
Pharmaceuticals sector
Allergan shares slip as judge invalidates patent on top selling eyedrop
...The Texas judge said the intellectual property was invalid, opening the way for generic competitors Mylan and Teva to market a cheaper copycat version of the prescription eye drop Restasis....
October 16, 2017
Pharmaceuticals sector
Allergan to cut more than 1,000 jobs as it seeks to lower costs
...October struck down a patent protecting its second-best seller, Restasis — a prescription eye drop, which generated roughly $1.5bn in sales for Allergan in 2016 — and flung open the doors to competitors like Mylan...
January 3, 2018

Previous pagePage 1 of 6Next page